Nitroindazole compounds inhibit the oxidative activation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to neurotoxic pyridinium cations by human monoamine oxidase (MAO)

References

• Kalgutkar AS, Dalvie DK, Castagnoli N, Taylor TJ. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol 2001; 14: 1139–1162
   PubMed Web of Science ®Google Scholar
• Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 2006; 7: 295–309
   PubMed Web of Science ®Google Scholar
• Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Ann Rev Neurosci 1999; 22: 197–217
   PubMed Web of Science ®Google Scholar
• Yamada M, Yasuhara H. Clinical pharmacology of MAO inhibitors: safety and future. Neurotoxicology 2004; 25: 215–221
   PubMed Web of Science ®Google Scholar
• Samantaray S, Knaryan VH, Butler JT, Ray SK, Banik NL. Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP. J Neurochem 2008; 104: 1309–1320
   Google Scholar
• Lee DW, Sohn HO, Lim HB, Lee YG, Kim YS, Carp RI, Wisniewski HM. Alteration of free radical metabolism in the brain of mice infected with scrapie agent. Free Radic Res 1999; 30: 499–507
   PubMed Web of Science ®Google Scholar
• Cohen G, Farooqui R, Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci USA 1997; 94: 4890–4894
   PubMed Web of Science ®Google Scholar
• Hauptmann N, Grimsby J, Shih JC, Cadenas E. The metabolism of tyramine by monoamine oxidase A/B causes oxidative damage to mitochondrial DNA. Arch Biochem Biophys 1996; 335: 295–304
   PubMed Web of Science ®Google Scholar
• Youdim MBH, Lavie L. Selective MAO-A and MAO-B inhibitors, radical scavengers and nitric oxide synthase inhibitors in Parkinson's disease. Life Sci 1994; 55: 2077–2082
   PubMed Web of Science ®Google Scholar
• Langston JW, Irwin I, Langston EB, Forno LS. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 1984; 48: 87–92
   PubMed Web of Science ®Google Scholar
• Herraiz T, Guillén H, Arán VJ, Idle JR, Gonzalez FJ. Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated β-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Toxicol Appl Pharmacol 2006; 216: 387–398
   PubMed Web of Science ®Google Scholar
• Herraiz T, Guillen H, Galisteo J. N-methyltetrahydro-β-carboline analogs of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin are oxidized to neurotoxic β-carbolinium cations by heme peroxidases. Biochem Biophys Res Commun 2007; 356: 118–123
   PubMedGoogle Scholar
• Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–980
   PubMed Web of Science ®Google Scholar
• Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ. Chronic Parkinsonism secondary to intravenous injection of meperidine analogs. Psychiatry Res 1979; 1: 249–254
   PubMed Web of Science ®Google Scholar
• Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism. Nature 1984; 311: 464–467
   PubMed Web of Science ®Google Scholar
• Chiueh CC, Krishna G, Tulsi P, Obata T, Lang K, Huang SJ, Murphy DL. Intracranial microdialysis of salicylic acid to detect hydroxyl radical generation through dopamine autooxidation in the caudate nucleus. Effects of MPP+. Free Radic Biol Med 1992; 13: 581–583
   PubMed Web of Science ®Google Scholar
• Obata T. Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping. Toxicol Lett 2002; 132: 83–93
   Google Scholar
• Thomas B, Saravanan KS, Mohanakumar KP. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Neurochem Int 2008; 52: 990–1001
   PubMed Web of Science ®Google Scholar
• Gonzalez-Polo RA, Soler G, Rodriguez Martin A, Moran JM, Fuentes JM. Protection against MPP+ neurotoxicity in cerebellar granule cells by antioxidants. Cell Biol Int 2004; 28: 373–380
   PubMedGoogle Scholar
• Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007; 2: 141–151
   PubMed Web of Science ®Google Scholar
• Nolen WA, Hoencamp E, Bouvy PF, Haffmans PMJ. Reversible monoamine oxidase-A inhibitors in resistant major depression. Clin Neuropharmacol 1993; 16: S69–S76
   PubMed Web of Science ®Google Scholar
• Ben-Shlomo Y, Bhatia K. Using monoamine oxidase type B inhibitors in Parkinson's disease: they are effective and safe, at least when used alone. BMJ 2004; 329: 581–582
   Google Scholar
• Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: (-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 2005; 326: 378–386
   PubMed Web of Science ®Google Scholar
• Castagnoli K, Murugesan T. Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?. Neurotoxicology 2004; 25: 279–291
   PubMed Web of Science ®Google Scholar
• Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 1996; 93: 14065–14069
   PubMed Web of Science ®Google Scholar
• Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, Warner D, Zezulkova I, Cilento R. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379: 733–736
   PubMed Web of Science ®Google Scholar
• Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B, Hirsch EC. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res 2003; 984: 224–232
   PubMed Web of Science ®Google Scholar
• Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli N. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol 1997; 10: 364–368
   PubMed Web of Science ®Google Scholar
• Grandi T, Sparatore F, Gnerre C, Crivori P, Carrupt PA, Testa B. Monoamine oxidase inhibitory properties of some benzazoles: structure-activity relationships. AAPS Pharmsci 1999; 1: 1–4
   Google Scholar
• Cerecetto H, Gerpe A, Gonzalez M, Aran VJ, Ochoa de Ocariz C. Pharmacological properties of indazole derivatives: recent developments. Mini-Rev Med Chem 2005; 5: 869–878
   PubMed Web of Science ®Google Scholar
• Babbedge RC, Blandward PA, Hart SL, Moore PK. Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br J Pharmacol 1993; 110: 225–228
   PubMed Web of Science ®Google Scholar
• Wolff DJ, Gribin BJ. The Inhibition of the constitutive and inducible nitric-oxide synthase isoforms by indazole agents. Arch Biochem Biophys 1994; 311: 300–306
   PubMedGoogle Scholar
• Schulz JB, Matthews RT, Muqit MMK, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995; 64: 936–939
   PubMed Web of Science ®Google Scholar
• Boireau A, Dubedat P, Bordier F, Imperato A, Moussaoui S. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP+ accumulation. Neuropharmacology 2000; 39: 1016–1020
   PubMed Web of Science ®Google Scholar
• Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT, Beal MF. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 1996; 2: 1017–1021
   PubMed Web of Science ®Google Scholar
• Watanabe H, Muramatsu Y, Kurosaki R, Michimata M, Matsubara M, Imai Y, Araki T. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study. Eur Neuropsychopharmacol 2004; 14: 93–104
   PubMed Web of Science ®Google Scholar
• Di Monte DA, Royland JE, Anderson A, Castagnoli K, Castagnoli N, Langston JW. Inhibition of monoamine oxidase contributes to the protective effect of 7-nitroindazole against MPTP neurotoxicity. J Neurochem 1997; 69: 1771–1773
   Google Scholar
• Desvignes C, Bert L, Vinet L, Denoroy L, Renaud B, Lambas-Senas L. Evidence that the neuronal nitric oxide synthase inhibitor 7-nitroindazole inhibits monoamine oxidase in the rat: in vivo effects on extracellular striatal dopamine and 3,4-dihydroxyphenylacetic acid. Neurosci Lett 1999; 261: 175–178
   PubMed Web of Science ®Google Scholar
• Muramatsu Y, Kurosaki R, Mikami T, Michimata M, Matsubara M, Imai Y, Kato H, Itoyama Y, Araki T. Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice. Metab Brain Dis 2002; 17: 169–182
   PubMed Web of Science ®Google Scholar
• Royland JE, Delfani K, Langston JW, Janson AM, Di Monte DA. 7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse striatum. Brain Res 1999; 839: 41–48
   Google Scholar
• Rojas P, Rojas C, Ebadi M, Montes S, Monroy-Noyola A, Serrano-Garcia N. EGb761 pretreatment reduces monoamine oxidase activity in mouse corpus striatum during 1-methyl-4-phenylpyridinium neurotoxicity. Neurochem Res 2004; 29: 1417–1423
   Google Scholar
• Fuller RW, Hemrickluecke SK. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Life Sci 1985; 37: 1089–1096
   Google Scholar
• Matsumura N, Kikuchi-Utsumi K, Nakaki T. Activities of 7-nitroindazole and 1-(2-(trifluoromethylphenyl)-imidazole independent of neuronal nitric-oxide synthase inhibition. J Pharmacol Exp Ther 2008; 325: 357–362
   Google Scholar
• Aran, VJ, Flores, M, Muñoz, P, Paez, JA, Sanchez-Verdu, P, Stud, M. Analogues of cytostatic, fused indazolinones: Synthesis, conformational analysis and cytostatic activity against HeLa cells of some 1-substituted indazolols, 2-substituted indazolinones, and related compounds. Liebigs Ann 1996;683–691.
   Google Scholar
• Aran, VJ, Asensio, JL, Ruiz, JR, Stud, M. Reactivity of 1,1-disubstituted indazol-3-ylio oxides—synthesis of some substituted indazolols and indazolinones. J Chem Soc Perkin Trans 1 1993;1119–1127.
   Google Scholar
• Herraiz T, Chaparro C. Analysis of monoamine oxidase enzymatic activity by reversed-phase high performance liquid chromatography and inhibition by β-carboline alkaloids occurring in foods and plants. J Chromatogr A 2006; 1120: 237–243
   PubMedGoogle Scholar
• Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 1999; 26: 1231–1237
   PubMed Web of Science ®Google Scholar
• Herraiz T, Galisteo J. Endogenous and dietary indoles: a class of antioxidants and radical scavengers in the ABTS assay. Free Radic Res 2004; 38: 323–331
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol 1990; 186: 1–85
   PubMed Web of Science ®Google Scholar
• Gutteridge JMC. Ferrous-salt-promoted damage to deoxyribose and benzoate. The increased effectiveness of hydroxyl radical scavangers in the presence of EDTA. Biochem J 1987; 243: 709–714
   PubMed Web of Science ®Google Scholar
• Cheng Y-C, Prussoff WF. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099–3108
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JMC, Aruoma OI. The deoxyribose method: a simple test-tube assay for determination of rate constants for reactions of hydroxyl radicals. Anal Biochem 1987; 165: 215–219
   PubMed Web of Science ®Google Scholar
• Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984; 311: 467–469
   PubMed Web of Science ®Google Scholar
• Chiba K, Trevor A, Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984; 120: 574–578
   PubMed Web of Science ®Google Scholar
• Cutillas B, Espejo M, Ambrosio S. 7-Nitroindazole prevents dopamine depletion caused by low concentrations of MPP+ in rat striatal slices. Neurochem Int 1998; 33: 35–40
   Google Scholar
• Di Matteo V, Benigno A, Pierucci M, Giuliano DA, Crescimanno G, Esposito E, Di Giovanni G. 7-Nitroindazole protects striatal dopaminergic neurons against MPP+-induced degeneration: an in vivo microdialysis study. Ann NY Acad Sci 2006; 1089: 462–471
   PubMed Web of Science ®Google Scholar
• Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 2002; 9: 22–26
   PubMedGoogle Scholar
• Krueger MJ, Mazouz F, Ramsay RR, Milcent R, Singer TP. Dramatic species differences in the susceptibility of monoamine oxidase B to a group of powerful inhibitors. Biochem Biophys Res Commun 1995; 206: 556–562
   PubMed Web of Science ®Google Scholar
• Cleeter MWJ, Cooper JM, Schapira AHV. Nitric oxide enhances MPP+ inhibition of complex I. FEBS Lett 2001; 504: 50–52
   Google Scholar
• Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003; 53: S26–S36
   PubMed Web of Science ®Google Scholar
• Bostanci MO, Bagirici F. Neuroprotection by 7-nitroindazole against iron-induced hippocampal neurotoxicity. Cell Mol Neurobiol 2007; 27: 933–941
   Google Scholar
• Reiter RJ, Tan DX, Allegra M. Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactants. Neuroendocrinol Lett 2002; 23: 3–8
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Kato H, Araki T. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease. Metab Brain Dis 2008; 23: 51–69
   Google Scholar